OBJECTIVE: Noninvasive assessment of the immediate and delayed cardiopulmonary response to a 2% aminophylline-based topical thigh reducing cream. DESIGN: Prospective, double-blind, randomized, counterbalanced study with application of: no cream (NC), placebo cream (PC) or 2% aminophylline cream (AC). SUBJECTS: Nine healthy women (aged: 23 AE 3 y; weight: 58 AE 3 kg; height: 165 AE 7 cm; body fat: 19 AE 6%; estimated maximal aerobic ®tness VO 2 max): 40 AE 4 mlakgamin). MEASUREMENTS: Medical history, skin patch test, skinfolds, YMCA submaximal cycle ergometry test, psychological evaluations (POMS and Speilberger STAI-1). Pulmonary function and spectral analysis on heart rate variability, measured immediately post-and 4 h post-treatment, on three separate days within a three-week period. RESULTS: Pulmonary function did not change. The averaged R-R interval (ms) was signi®cantly lower for the immediate post AC treatment, but returned to baseline in 4 h. CONCLUSION: Application of a 2% aminophylline-based thigh cream does not affect pulmonary function, however, it may cause a temporary, transient reduction in the averaged R-R interval.
Introduction
Aminophylline-based creams have become available over-the-counter as potential cosmetic fat-reducing topical agents for the thighs, largely due to the success reported on a series of small studies in one scienti®c publication. 1 According to Greenway et al, 1 when 0.5 ± 10% aminophylline-based topical agents were applied to one thigh in women who were either overweight or felt they had undesirably fat thighs, signi®cant reductions in girth were reported. Whilè signi®cant' girth reduction occurred in the treated thigh, many women also had girth reductions in the placebo treated thigh as well, presumably due to concurrent participation in a variety of diet and exercise programs. Conversely, a study conducted with 11 women at the Washington University School of Medicine failed to ®nd changes in girth or skinfolds in the treated thighs. 2, 3 While visceral fat patterning has more serious cardiovascular consequences than femoral fat, 4 the resistance to fat loss in the femoral region remains distressing to many women. Since women are going to use these creams for the potential cosmetic bene®t, a higher level of proof is needed to substantiate claims that the creams are safe, given that they offer no apparent health bene®t. 5 Similar safety concerns have been expressed by the Food and Drug Administration (FDA). 3, 6, 7, 8 Aminophylline, a common bronchorelaxant used for the treatment of asthma, is a methylxanthine derivative consisting of a 2:1 mixture of theophylline and ethylenediamine. 9 It acts as both a b 2 adrenergic agonist as well as an adenosine antagonist. Hence, its pharmacological actions may include relaxation of smooth muscle (bronchioles), central nervous system (CNS) stimulation and cardiac muscle stimulation. Since adenosine inhibits hormone-induced lipolysis, blocking adenosine receptors may encourage fat breakdown. Women have more adenosine A 2 receptors in the femoral region in comparison to the abdominal region. 1 This may render femoral fat to be less metabolically active than abdominal fat and thus more resistant to fat loss. Consequently, it has been hypothesized that application of an aminophylline cream, when absorbed in the thighs, may block A 2 receptors and facilitate the breakdown of resistant fat storage. 1 There are currently over 50 different aminophylline-based creams on the market, ranging in price from $10 ± $30 per bottle. 7 Since daily use is advocated for the cosmetic change in appearance of the thighs, a year's supply of this product can cost the consumer up to $900. Despite unclear ef®cacy or cost, detailed studies of potential cardiopulmonary effects have not been undertaken. Systemic administration of aminophylline is known to occasionally produce serious cardiopulmonary side effects. 9 Furthermore, a few consumers have reported that they experienced shortness of breath and palpitations upon using aminophylline-based thigh cream products. 7 Although it has been reported that a 2% aminophylline-based cream, as well as an experimental 10% aminophylline based cream, when applied topically, causes no immediate rise in blood levels of aminophylline, 1, 10 no study has investigated the acute or chronic changes in heart rate variability via spectral analylsis for insight into autonomic control nor pulmonary function in response to the application of such creams.
The primary purpose of this study was to investigate the immediate and delayed cardiopulmonary response to a controlled 2% dosing of an aminophylline-based fat reducing cream in healthy women. We hypothesized that heart rate variability (HRV) and pulmonary function tests (PFTs) would be sensitive noninvasive tools to detect any immediate or delayed cardiopulmonary responses to applications of the cream. We were also interested in whether perceived symptoms from cream applications would correspond with the cardiopulmonary responses.
Methods

Subjects
Twelve healthy premenopausal females volunteered to participate in this study. The study was approved by the Human Use Committees at the University of North Carolina at Chapel Hill and Florida Atlantic University in Boca Raton, Florida. Written informed consents were obtained from all of the subjects. Subjects were excluded from the study if they were: 1) on medications that might alter metabolic, cardiopulmonary or psychological function; 2) smokers; 3) pregnant, lactating or attempting to become pregnant; 4) aged b 30 y; 5) had an estimated maximal aerobic ®tness (VO 2 )`33 mlakgamin; 5) had an estimated body fat b 28%; 6) had skin allergies to cosmetic products or cream bases in body moisturizers; or 7) if they reported signi®cant weight loss or gain during the four months prior to potential study participation.
To ascertain that the subjects would not be sensitive to the creams being used, a standard dermatological skin-patch test was conducted. One ml of each aminophylline-based thigh cream 11 (1% aminophyllinebased cream: University Medical Original Thigh Cream, University Medical Products, Newport Beach, CA; 2% aminophylline-based cream: Thigh High, Faneuil Companies, Scottsdale, AZ) as well as a placebo cream (0% aminophylline, Publix-Brand Cocoa Butter Moisturizing Cream, Lakeland, FL) was placed on the underside of the subject's right arm. The placebo cream was of similar color, texture and aroma of both aminophylline-based test creams. The test site was covered with a large waterproofed bandage. Subjects were instructed to keep the area as dry as possible and to return to the lab for re-evaluation of the skin test site at 48 h. If no adverse reaction occurred, the subjects proceeded with the study. The subjects maintained their current lifestyle during participation in the study. Upon study completion, subjects were rewarded with free product samples of the test and placebo creams.
Height was measured in centimeters (cm) from a tape measure mounted on a wall and weight was measured on a Howe Balance Beam Scale (Rutland) to the nearest kilogram (kg). Percent body fat was estimated from the sum of three skinfold sites (tricep, suprailiac and thigh) using Lange Skinfold Calipers (Cambridge, MD).
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VO 2 max (in mlakgamin) was estimated from the multi-stage YMCA submaximal exercise test protocol on a cycle ergometer. 13 
Experimental protocol
Subjects were assigned at random to three counterbalanced treatment conditions, administered in a double-blind fashion on three different days: no cream (NC), placebo cream (PC) or 2% aminophylline-based cream (AC). They completed one 1.5 h morning session and one 30 min afternoon session, for each treatment condition. Testing was completed within three weeks for each subject.
During the morning session (07.00 ± 11.00 h), a baseline (BSL) measurement and an immediate post treatment (IPT) measurement was performed. Following the BSL measurement period, subjects were exposed to one of the three conditions (NC, PC, AC). If the condition was PC or AC, 4.5 g (5 ml) was applied to each thigh by the subject after BSL testing. The subject massaged the cream evenly onto the entire thigh region for one minute. After product application, the subject washed any remaining cream residue from her hands. During the NC condition, the subject washed her hands and sat quietly until IPT measurements began. The IPT morning measurements began 10 min after treatment administration. The afternoon measurement session was completed 4 h later (4 h post treatment, FPT).
The following pulmonary and cardiovascular dependent variables were measured at BSL, IPT and FPT: forced vital capacity (FVC), forced expiratory volume in 1 s (FEV 1 ), peak expiratory¯ow (PEF); heart rate (HR, bpm), standard deviation of the R-R interval (RRSD, ms); averaged R-R interval (RRMS); low frequency power (LF, 0.02 ± 0.06 hz); mid-frequency power (MF, 0.061 ± 0.15 hz); high-frequency power (HF, 0.151 ± 0.40 hz); and sympathovagal Each morning and afternoon session began with the subject completing a written recall verifying that she did not exercise, smoke, use tobacco or nicotine products, drink caffeinated beverages, eat chocolate or highly spiced foods, drink alcoholic beverages or take medications that might affect heart rate or pulmonary function. Non-exposure to cigarette smoke was veri®ed with a carbon monoxide (CO) expired air test (Vitalograph, Lenexa, KS). All CO levels were`5 ppm (1.8AE 1.4 ppm) 15 The subject, prepped with a 5-lead ECG (RA, LA, RL, LL, V 5 ), rested in a supine position for 20 min breathing to a metronome at a rate of 10 ± 12 breathsamin. The last 10 min of the 20 min period was recorded. Five minutes of the 10 min ECG recording was analyzed. The data was normalized to remove the dc side-lobe component and was zero padded when necessary to achieve 512 data points for the analysis. The heartbeats were analyzed using fast fourier transformation for spectral analysis. 16 
Statistical analyses
Descriptive statistics (means AE s.d.) were used to describe the subject population. The actual raw data vs normalized units were used for the spectral analysis, since it has been demonstrated that the validity of actual data are equivalent to normalized units. 17 Repeated measures ANOVA were used to determine signi®cant differences in anxiety level and cardiopulmonary function at BSL, IPT and FPT, as well as changes from BSL ± IPT and IPT ± FPT between treatment groups. When a signi®cant F ratio was found, Student Newman-Keuls and Paired-t post hoc tests were completed, to determine speci®c between group differences. For all analysis, alpha was set at the P`0.05 level of signi®cance.
Results
Twelve women were approved during telephone interviews, for participation in this study. During the physiological screenings, one was excluded because of an irregular heart rhythm, one because of a low aerobic ®tness level, and one because of an acutē are-up of seasonal allergies requiring medication. None of the women screened had dermatological reactions to any of the cream products. The remaining nine women who completed the study were aged 23.11 y ( AE 2.57), weighed 57.98 kg ( AE 3.1), had a body mass index (BMI) of 21.44 kgam 2 ( AE 1.19), an estimated body fat of 19.04% ( AE 6.07) and a predicted maximal aerobic capacity of 39.91 mlakgamin ( AE 3.95).
Since repeated measures ANOVA analysis showed no signi®cant differences between any of the morning or afternoon sessions, for the psychological evaluations (P b 0.30), only the combined mean values ( AE s.d.) of the morning and afternoon sessions were reported. The baseline morning POMS-T scores were 4.96 ( AE 3.4) while the afternoon scores averaged 6.52 ( AE 4.9). The STAI-Y1 form scores were 29.37 ( AE 5.9), while the afternoon scores were slightly lower (28.78 AE 7.2). Pulmonary function was not signi®cantly different at baseline between treatment conditions, nor during BSL-IPT and IPT-FPT, therefore only the averaged daily pulmonary function responses were listed in Table 1 . 
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There were no signi®cant differences for HR, RR s.d., low frequency power, mid frequency power, and the SP:HI ratio between or within treatments for the absolute values or the change scores of BSL ± IPT or IPT ± FPT. Table 1 lists the averaged daily cardiovascular responses to each treatment condition. As shown in Figure 1 , the absolute value for the averaged R-R interval (ms) was signi®cantly lower for the AC-IPT measurement period in comparison to all other measurement periods, however the change scores for this same variable were not signi®cantly different between treatments (P 5 0.08: BSL ± IPT, IPT ± FPT).
Repeated measures ANOVA showed a signi®cant difference in high frequency power between the measurement periods (P 0.013). A Student Newman-Keuls post-hoc analysis revealed an isolated signi®cant difference in high frequency power between NC ± IPT vs the PC-FPT measurement periods (Table 2) . Repeated measures analysis also demonstrated a signi®cant difference in the high frequency change scores for BSL ± IPT (P 0.01), but not for IPT ± FPT (P 0.99). Paired t-tests for the high frequency BSL ± IPT scores found NC`PC ( 7 0.43 vs 0.02, P 0.006), NC`AC ( 7 0.43 vs 7 0.12, P 0.73), and AC`PC ( 7 0.12 vs 0.02, P 0.28).
Discussion
All pulmonary function values were within normal range for all treatment conditions. The anxiety-tension scores were not elevated, thereby suggesting the subjects did not perceive the experimental treatments to be stressful. The application of the 2% aminophylline cream did not signi®cantly alter pulmonary function.
The signi®cant shortening of the averaged R-R interval IPT with the aminophylline cream (AC-IPT) suggests a potential acute decrease in parasympathetic control; however, this effect was short-lived as the response was not seen 4 h post (AC-FPT). Since the change from BSL ± IPT and the change from IPT ± FPT was not signi®cantly different for this variable between treatment conditions, it is questionable whether the lower absolute value of the averaged R-R intervals was truly due to the AC treatment. Additionally, spectral analysis did not demonstrate corresponding signi®cant reductions in the RR s.d. interval or HF power during the same measurement period. On the other hand, the lower AC treatment BSL ± IPT change value for high frequency power suggests lowered vagal tone, when compared to the BSL ± IPT change value for the PC condition, however this change was not statistically signi®cant.
The signi®cant reduction in high frequency power from BSL ± IPT for the NC condition suggests increased sympathetic tone. This was a curious ®nd-ing, perhaps re¯ecting subliminal agitation that a cream treatment was not received. All subjects verbally expressed minor disappointment when the NC treatment was announced. In retrospect, it may have been bene®cial to have had a NC massage condition in order to differentiate between the potential action of massage therapy vs psychological affect on the spectral measurements. Furthermore, the act of`doing nothing' may also have been anxiety producing, even if the subject was not consciously aware of it. Unfortunately, anxiety evaluations were not made at IPT. Any undisclosed concerns the subjects may have had at IPT, did not surface in their evaluations at FPT.
Another unexpected ®nding was that sympathovagal balance did not favour vagal control. It has been reported in the literature that controlled breathing techniques commonly employed during spectral analysis measurements tend to favour vagal control, resulting in SP:HI ratios of`1.00. 17 Although the lower heart rates and anxiety scores indicated that the subjects were not anxious, the SP:HI ratios in this study were all elevated above 1.00, suggesting increased sympathetic tone for all treatment conditions. 
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It may be that controlled metronomic breathing was perceived as dif®cult thereby overriding vagal dominance. Alternatively, since all of the subjects were relatively inexperienced research subjects, the mere act of being a subject may have unknowingly exerted some in¯uence, which was then detected in this aspect of the spectral analysis.
Conclusions
Topical application of this 2% aminophylline-based thigh reducing cream caused no adverse dermatological reactions, nor did it enhance or adversely affect pulmonary function. This 2% aminophylline-based cream may have caused an acute, temporary increase in sympathetic activity within 10 min of product application. Given this immediate autonomic response, it is unclear whether this cream has the potential to interact with common medications prescribed for cardiovascular disorders. However, no other acute or delayed cardiovascular effects were seen in response to a single dosing of the AC. While the results from this study suggest that this 2% aminophylline-based cream is relatively innocuous in healthy non-pregnant females, this and many other cosmetic thigh cream products have not undergone rigorous animal testing. Therefore, it is unknown if any side effects could occur in pregnant or lactating women. Other than expressing disappointment when a cream treatment was not received, the subjects did not report feeling anxious, nor did they report feeling any alterations in their breathing or heart rate response during any treatment condition. Since this study employed a small, select subject sample, future research should investigate whether similar results would be obtained in less ®t, less healthy individuals with larger body masses.
